Shire Receives New Paragraph IV Notice Letter From Watson for ADDERALL XR

Shire plc SHPGY announces that its subsidiaries Shire LLC and Shire Development Inc. have received a new Paragraph IV Notice Letter from Watson Laboratories, Inc. in Fort Lauderdale, Florida advising of the filing of an Abbreviated New Drug Application for a generic version of all approved strengths of Shire's ADDERALL XR dextroamphetamine sulphate, dextroamphetamine saccharate, amphetamine aspartate monohydrate, amphetamine sulphate capsules, CII. The new ANDA that Watson filed is not covered under the existing settlement agreements entered into in November 2007 between Shire and Watson (the "Settlement Agreements"). The Settlement Agreements cover a different ANDA and do not provide any license for Watson to sell the products covered in Watson's new ANDA.